{"i": ["Peg - IFN alfa - 2a", "sofosbuvir - based", "IFN - free", "peginterferon ( Peg - IFN ) plus ribavirin ( RBV ).", "erythropoiesis - stimulating agent ( ESA )", "Peg - IFN plus weight - based RBV", "sofosbuvir ( SOF )- based", "Peg - IFN plus RBV therapy", "RBV", "Peg - IFN plus weight - based RBV therapy", "Peginterferon plus weight - based ribavirin", "sofosbuvir", "weight - based RBV", "Peg - IFN plus RBV", "peginterferon ( Peg - IFN ) plus ribavirin ( RBV ) treatment"], "o": ["AEs", "stage of hepatic fibrosis", "hemogram , biochemical assays ( serum albumin , bilirubin , AST , ALT , and creatinine ), serologic assays ( anti - HCV , HBsAg , and anti - HIV ), virologic assays ( HCV RNA", "virologic responses ( including EVR , and ETVR ),", "rates of anemia", "end - of - treatment virologic response ( ETVR )", "baseline viral load , subgenotype", "SVR rate", "SVR .", "safety", "viral response", "IL - 28B genotypes", "undetectable serum HCV RNA", "BMI , APRI score", "sustained virologic response ( SVR ).", "Serial serum HCV RNA levels", "SVR", "sustained virologic response ( SVR ) rates", "cirrhosis", "AE - related withdrawal rates", "ETVR", "serious AEs", "anti - HCV antibody", "constitutional or laboratory AEs", "EVR", "SVR rates", "Significant hepatic fibrosis", "relapse rates", "viral breakthrough", "early virologic response ( EVR )", "aspartate aminotransferase ( AST )- to - platelet ratio index ( APRI ) score", "serious AE rates", "rapid virologic response ( RVR )", "constitutional and laboratory AE rates", "constitutional and laboratory adverse events ( AEs", "RBV", "posttreatment virologic response ( including SVR ),", "viral load"]}